<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786992</url>
  </required_header>
  <id_info>
    <org_study_id>AS1301</org_study_id>
    <nct_id>NCT02786992</nct_id>
  </id_info>
  <brief_title>Misoprostol+Oxytocin vs. Carbetocin in CS</brief_title>
  <acronym>CS</acronym>
  <official_title>Adjuvant Use of Misoprostol and Oxytocin vs. Carbetocin for the Prevention of Post-partum Hemorrhage in Elective Cesarian Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <brief_summary>
    <textblock>
      This prospective randomized double-blind clinical trial will be conducted at Ain-Shams
      University Maternity Hospital, Cairo, Egypt. Patients eligible for elective lower segment
      cesarean section will be randomized to 2 groups. Group 1: will receive 400 ug misoprostol
      following + 10 IU oxytocin intravenous slowly after cord clamping. Group 2: will receive 100
      ug carbetocin intravenous after cord clamping.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of post-partum hemorrhage</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amount of blood loss</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants needing extra uterotonic drug (10 IU oxytocin IVI)</measure>
    <time_frame>24 hours</time_frame>
    <description>An experienced attendant (principal investigator) will assess the need of extra uterotonic drug (10 IU oxytocin IVI) if the uterus is atonic or if blood loss is more than 1000 ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants needing hemostatic surgical interventions</measure>
    <time_frame>intra-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin deficit in gm/dl</measure>
    <time_frame>24 hours</time_frame>
    <description>difference between pre-operative and 24 hours post-operative hemoglobin in gm/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score at 1 minute and 5 minutes</measure>
    <time_frame>1 minute and 5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with NICU admission</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug side effects</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till resuming bowel habits</measure>
    <time_frame>24 hours</time_frame>
    <description>Time of passing gas will be recorded how many hours post-operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematocrit deficit in %</measure>
    <time_frame>24 hours</time_frame>
    <description>difference between pre-operative and 24 hours post-operative hematocrit in %</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Misoprostol + Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 ug sublingual misoprostol + 10 IU Oxytocin IVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 ug Carbetocin IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>Misoprostol + Oxytocin</arm_group_label>
    <other_name>Mesotec</other_name>
    <other_name>Mesotac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Misoprostol + Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Misoprostol + Oxytocin</arm_group_label>
    <arm_group_label>Carbetocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with singleton pregnancy Women scheduled for elective CS full term (gestational
             age â‰¥37 weeks).

        Exclusion Criteria:

          -  hypersensitivity to oxytocin, carbetocin or prostaglandins

          -  contraindication to prostaglandins (e.g. glaucoma)

          -  history of significant heart disease

          -  severe asthma

          -  epilepsy

          -  history or evidence of liver

          -  renal or vascular disease

          -  history of coagulopathy

          -  thrombocytopenia or anticoagulant therapy

          -  women with HELLP syndrome

          -  eclampsia

          -  women presenting by placental abruption

          -  contraindication to spinal anesthesia as carbetocin is licensed for use with regional
             anesthesia only.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Carbetocin</keyword>
  <keyword>Prevention</keyword>
  <keyword>Post-partum hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

